Hospitals with a higher volume of percutaneous microaxial ventricular assist device implantation in the US have fewer deaths among cardiogenic shock patients.

Study to be conducted under $3.6 million NIH grant DENVER, Jan. 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), ...

SeaStar Medical (ICU) announced that the U.S. FDA has approved an investigational device exemption application to evaluate ...

The study examined 52 heart failure patients, including 28 who received a left ventricular assist device (LVAD), a surgically ...

Patients with cardiogenic shock treated at hospitals with a higher volume of percutaneous microaxial VAD implantation in the US have lower mortality risk. Higher hospital procedure volume of ...

The ARIES-HM3 trial analysis found that in advanced heart failure patients with traditional indications for antiplatelet ...

Physicians at Emory University Hospital performed the first-ever surgical implantation in the United ... known as a ventricular assist device, or VAD, with the brand name of BrioVAD System.

Clinical Electrophysiology journal showed that when acute procedural success is attained in a subset of patients with ...

Injecting infarcted pig hearts with specially bioengineered cells significantly decreased the infarct area and improved heart ...

of an average age of 2 months (±1.9 months SD), underwent shunt implantation. The size of the ventricular system was described by the Frontal Horn Index and its change after operative procedures ...

Discover the innovative AVEIR leadless pacemaker, a groundbreaking solution for conventional pacemaker therapy issues with leads and pulse generators.

Of the implanted pacemakers, 83% were dual chamber and 17% single chamber ventricular devices. The indications for PPM implantation were high-degree AV block in 55% of the cases and bradycardia in ...